CO4940453A1 - NEW METHOD OF TREATMENT WITH ANTI-HYPERGLYCEMIC INHIBITORS OF ALFAGLUCOSIDA- SA FOR TREATMENT OF DIABETES - Google Patents

NEW METHOD OF TREATMENT WITH ANTI-HYPERGLYCEMIC INHIBITORS OF ALFAGLUCOSIDA- SA FOR TREATMENT OF DIABETES

Info

Publication number
CO4940453A1
CO4940453A1 CO98034648A CO98034648A CO4940453A1 CO 4940453 A1 CO4940453 A1 CO 4940453A1 CO 98034648 A CO98034648 A CO 98034648A CO 98034648 A CO98034648 A CO 98034648A CO 4940453 A1 CO4940453 A1 CO 4940453A1
Authority
CO
Colombia
Prior art keywords
treatment
alfaglucosida
diabetes
new method
hyperglycemic
Prior art date
Application number
CO98034648A
Other languages
Spanish (es)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham filed Critical Smithkline Beecham
Publication of CO4940453A1 publication Critical patent/CO4940453A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composición de uso médico para el tratamiento de la diabetesmellitus y las condiciones asociadas con la misma, caracterizada por comprender en dosis eficaz no tóxica un sensibilizador a insulina y un agente antihiperglucémico inhibidor de alfa glucosidasa y un vehículo farmacéuticamente aceptable para la misma.1Composición según el punto 1 y 2 en la cual el agente anti-hiperglucémico inhibidor de alfa-glucosidasa es un emiglitato o miglitol.Composition for medical use for the treatment of diabetesmellitus and the conditions associated with it, characterized in that it comprises in an effective non-toxic dose an insulin sensitizer and an anti-hyperglycemic agent that inhibits alpha glucosidase and a pharmaceutically acceptable vehicle for it.1 Composition according to point 1 and 2 in which the alpha-glucosidase inhibiting anti-hyperglycemic agent is an emiglitate or miglitol.

CO98034648A 1997-06-18 1998-06-18 NEW METHOD OF TREATMENT WITH ANTI-HYPERGLYCEMIC INHIBITORS OF ALFAGLUCOSIDA- SA FOR TREATMENT OF DIABETES CO4940453A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
CO4940453A1 true CO4940453A1 (en) 2000-07-24

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98034648A CO4940453A1 (en) 1997-06-18 1998-06-18 NEW METHOD OF TREATMENT WITH ANTI-HYPERGLYCEMIC INHIBITORS OF ALFAGLUCOSIDA- SA FOR TREATMENT OF DIABETES

Country Status (24)

Country Link
EP (1) EP0975343A1 (en)
JP (1) JP2001523271A (en)
KR (1) KR20010013845A (en)
CN (1) CN1274282A (en)
AP (1) AP9901720A0 (en)
AR (2) AR014881A1 (en)
AU (1) AU8799998A (en)
BG (1) BG103966A (en)
BR (1) BR9810186A (en)
CA (1) CA2294134A1 (en)
CO (1) CO4940453A1 (en)
DZ (1) DZ2519A1 (en)
EA (1) EA200000040A1 (en)
IL (1) IL133138A0 (en)
MA (1) MA26510A1 (en)
NO (1) NO996270D0 (en)
NZ (1) NZ501345A (en)
OA (1) OA11631A (en)
PE (1) PE89199A1 (en)
PL (1) PL337577A1 (en)
SK (1) SK179499A3 (en)
TR (1) TR199903072T2 (en)
UY (1) UY25051A1 (en)
WO (1) WO1998057635A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009934A (en) 1999-04-23 2002-06-04 Smithkline Beecham Plc Pharmaceutical
CA2443325C (en) 2001-04-04 2011-06-14 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
ATE423559T1 (en) 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm COMBINATION THERAPY USING GLUCOSE ABSORPTION INHIBITORS AND PPAR MODULATORS
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
JP2004067575A (en) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd Promoter for effect of therapeutic agent for diabetes
CN101121004B (en) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 Medicine composition containing insulin intensifier and miglitol
CN101584705B (en) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes
CN101584688B (en) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 Medicament composition for treating diabetes and complications of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510286A (en) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone, glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AP9901720A0 (en) 1999-12-31
IL133138A0 (en) 2001-03-19
NO996270L (en) 1999-12-17
PL337577A1 (en) 2000-08-28
BR9810186A (en) 2000-08-08
CA2294134A1 (en) 1998-12-23
OA11631A (en) 2004-11-22
AR014881A1 (en) 2001-04-11
CN1274282A (en) 2000-11-22
SK179499A3 (en) 2000-11-07
EA200000040A1 (en) 2000-08-28
KR20010013845A (en) 2001-02-26
TR199903072T2 (en) 2000-07-21
DZ2519A1 (en) 2003-02-01
NO996270D0 (en) 1999-12-17
WO1998057635A1 (en) 1998-12-23
PE89199A1 (en) 1999-10-23
AR013352A1 (en) 2000-12-27
EP0975343A1 (en) 2000-02-02
JP2001523271A (en) 2001-11-20
BG103966A (en) 2000-07-31
UY25051A1 (en) 2000-09-29
AU8799998A (en) 1999-01-04
NZ501345A (en) 2001-10-26
MA26510A1 (en) 2004-12-20

Similar Documents

Publication Publication Date Title
NO2012015I1 (en) Dapoxetine in any form protected by base patent No. 330562
BR0111800A (en) Depeptidyl peptidase iv inhibitor combinations and other antidiabetic agents for the treatment of diabetes mellitus
BR0111196A (en) Compositions and use thereof for treatment of flaviviruses and pestiviruses
EA200100002A1 (en) BENZOTIEPINES, possessing the activity of inhibitors of the displacement of bile acids in the podzvodushny gut and absorption of taurholy
SE9404196D0 (en) New antithrombotic formulation
NO20024646D0 (en) Combination therapies with vasculature-damaging activity
ES2185660T3 (en) NEW USE OF DEXMEDETOMIDINE.
AR021912A1 (en) USE OF APOMORPHINE FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN VARONES
BR0009524A (en) Use of a compound, and, pharmaceutical or veterinary composition
CO4940453A1 (en) NEW METHOD OF TREATMENT WITH ANTI-HYPERGLYCEMIC INHIBITORS OF ALFAGLUCOSIDA- SA FOR TREATMENT OF DIABETES
PL333059A1 (en) Pharmaceutic agent containing adamantamines or structurally similar compounds for fighting against the borna disease virus (bdv) disease and preventing affective diseases as well as other diseases associated with bdv infections
AR019327A1 (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor
EA199901061A1 (en) NEW SALTS OF HRV-PEPTIDES WITH ORGANOPROTECTIVE ACTIVITY, METHOD OF THEIR RECOVERY AND THEIR USE IN THERAPY
ES2157984T3 (en) USE OF 4'-IODO-4'-DEOXIDOXORRUBICINE FOR THE TREATMENT OF AMIDOIDOSIS.
IT1295954B1 (en) USE OF A CHEMICAL AGENT TO DECREASE THE VARIATIONS IN LIFE AND THE CONSTIPATION EFFECT RELATED TO THE RECRUITMENT OF OTHER AGENTS
PT774961E (en) USE OF SELEGILINE FOR THE TREATMENT OF EPILEPTIC DISEASES
BR0317772A (en) Method of treating a behavioral disorder, use of a compound, and therapeutic agent for a behavioral disorder
EA200100041A1 (en) METHOD OF TREATMENT
ES2193285T3 (en) NITRIC OXIDE INHIBITOR (NO) - SYNTHEASE TO PREVENT TYPE II DIABETES.
ECSP982592A (en) NEW METHOD OF TREATMENT V
UY26735A1 (en) METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS
ES2025787T3 (en) WOOD TREATMENT PROCEDURE.
CO5270004A1 (en) PHARMACEUTICAL COMPOSITIONS WITH BIGUANIDA TYPE AGENT FOR DIABETES TREATMENTS
AR009470A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BACTERIAL STRAINS AND USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH OR CAUSED BY ALTERATIONS IN THE METABOLISM OF BILE ACIDS, AND USE OF THE SAME.